Skip to main content

Table 1 Comparison of baseline characteristics between two treatment protocols before and after propensity score matching

From: Pretreatment with oral contraceptives benefit POSEIDON group 1 low prognosis patients during GnRH-antagonist protocol: a propensity score-matched retrospective cohort study

Variable

Before matching

After matching

OCs

(n = 401)

non-OCs

(n = 1821)

P value

OCs

(n = 369)

non-OCs

(n = 879)

P value

Age (years)

32.35 ± 4.04

35.64 ± 5.09

0.*

33.54 ± 3.84

33.70 ± 3.75

0.414

BMI (kg/m2)

23.01 ± 3.47

22.73 ± 3.25

0.219

23.02 ± 3.47

22.62 ± 3.22

0.111

Infertility duration (years)

3.38 ± 2.59

3.71 ± 3.11

0.229

3.40 ± 2.65

3.63 ± 2.82

0.205

Type of infertility

      

 Primary n (%)

148(36.9)

863(47.4)

0.*

137(37.1)

348(39.1)

0.415

 Secondary n (%)

253(63.1)

958(52.6)

 

232(62.9)

531(60.4)

 

AMH (ng/ml)

1.91 ± 1.27

1.34 ± 1.13

0.*

1.84 ± 1.21

1.69 ± 1.20

0.690

AFC (n)

9.16 ± 4.05

7.24 ± 4.02

0.*

8.38 ± 3.73

8.20 ± 3.71

0.712

Basal E2 (pg/ml)

46.88 ± 22.57

46.49 ± 22.65

0.994

47.40 ± 22.72

46.00 ± 21.63

0.496

Basal FSH (IU/L)

8.73 ± 4.30

9.72 ± 4.48

0.*

8.89 ± 4.45

9.04 ± 3.47

0.531

Basal LH (IU/L)

4.63 ± 2.56

4.21 ± 2.56

0.107

4.58 ± 2.47

4.12 ± 2.14

0.162

  1. All values presented as mean ± SD or n (%)
  2. OCs, oral contraceptives; BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estrogen
  3. * indicates statistically significant of P<0.05
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us